Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Deciphera Pharmaceuticals reports robust Q4 performance and eyes market expansion

Deciphera Pharmaceuticals delivered strong financial results and outlined strategic priorities for future growth.
The company's focus on ctDNA analysis, market expansion, and potential label expansions position them well for continued success.
While facing uncertainties in guideline updates and market competition, Deciphera Pharmaceuticals remains optimistic about growth opportunities.

Deciphera Pharmaceuticals excels in Q1 2023, eyes international expansion

Deciphera Pharmaceuticals demonstrates strong financial performance and strategic achievements in Q1 2023, positioning the company for continued growth and market success.
While facing challenges from market dynamics and competition, the company's focus on international expansion, new drug development, and commercialization efforts presents promising opportunities.
By leveraging strengths in reimbursement ratings, clinical significance of key drugs, and pre-commercial activities, Deciphera is poised to capitalize on market opportunities and drive future growth.

Deciphera Pharmaceuticals excels in Q2, eyes international growth and innovation

Deciphera Pharmaceuticals delivered a standout performance in Q2 2023, driven by QINLOCK's robust revenue generation and international expansion.
While facing challenges such as high operating expenses and clinical trial complexities, the company remains focused on patient outcomes and program advancements.
Opportunities lie in continued revenue growth, clinical program progress, and leadership transitions, positioning Deciphera for future success and innovation.

Deciphera Pharmaceuticals excels in Q3 with record sales and innovative pipeline

Deciphera Pharmaceuticals shows strong financial and clinical performance in Q3 2023.
Balancing successful study outcomes with potential regulatory challenges and patient dynamics.
Company poised for significant revenue growth and market expansion with innovative products.
Continued focus on commercial success and pipeline advancement to drive future growth.

Deciphera Pharmaceuticals reports robust Q4 performance and eyes global expansion

Deciphera Pharmaceuticals showcased strong financial performance, clinical advancements, and strategic plans for growth in Q4 2023, positioning the company for continued success.
While facing challenges in market differentiation and operational execution, the company has opportunities for market expansion, record sales, and clinical development milestones in 2024.
Overall, Deciphera Pharmaceuticals' focus on QINLOCK sales, vimseltinib development, and international expansion underscores a comprehensive growth strategy and potential for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.60 per share a year ago.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “QINLOCK delivered record performance in the second quarter based on continued growth in the U.S. and around the world. Moving into a significant second hal.

Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company's Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appoi.

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2023 financial results on Wednesday, August 9, 2023. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, August 9, 2023,.

Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023

After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current prices make it quite attractive.

Deciphera Is A Buy In Expectation Of A Significant Comeback

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023. “As we prepare to initiate our INSIGHT pivotal Phase 3 study of QINLOCK versus sunitinib in.

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY. A live webcast of the fireside chat will be available on the “Events and Pre.

Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Jen Larson - Senior Vice President-Finance and Investor Relations Steve Hoerter - President and Chief Executive Officer Matt Sherman - Chief Medical Officer Dan Martin - Chief Commercial Officer Margarida Duarte - Head of International Tucker Kelly - Chief Financial Officer Conference Call Participants Tyler Van Buren - Cowen Bradley Canino - Stifel Reni Benjamin - JMP Securities Andrew Berens - SVB Securities Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2023 Financial Results Conference Call. Later, we will conduct a question-and-answer session.

Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.80 per share a year ago.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We have had a very strong start to 2023, achieving significant milestones including the completion of enrollment for the MOTION pivotal Phase 3 study of vi.

Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Know

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 3, 2023, to disc.

Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET.

Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days

Last year, Deciphera Pharmaceuticals, Inc. was almost destroyed by a trial failure. This year, Deciphera Pharmaceuticals has demonstrated huge benefit in a subpopulation, and also progressed the rest of its pipeline.

Deciphera Pharmaceuticals: In The Middle Of A Major Comeback (Upgrade)

Deciphera has a strong portfolio of investigational kinase inhibitors, including ripretinib, vimseltinib, and DCC-3116, that have demonstrated encouraging preliminary efficacy and safety data in treating various types of cancer. The company has completed enrollment in the pivotal Phase 3 MOTION study of vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT), with top-line results expected in Q4 2023.

Deciphera Pharmaceuticals: INTRIGUE Phase 3 Shows Substantial Benefit

Deciphera focuses on oncology therapies. The company's lead therapy is Qinlock, approved to treat patients with gastrointestinal stromal tumors.

Why Deciphera Pharmaceuticals Stock Jumped This Week

The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.

Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023. The Company will also host a virtual investor event on Tuesday, April 18 at 6:30 PM ET.

Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 7.1% Since Last Earnings Report?

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the completion of enrollment in the pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT) not amenable to surgery. Deciphera expects to report top-line results in the fourth quarter of 2023.

Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT

Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.

News for Deciphera Pharmaceuticals Stock (DCPH)